Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The incentive to treat: Physician agency and the expansion of the 340B drug pricing program.
J Health Econ
February 2025
Department of Clinical Pharmacy, Center for Translational and Policy Research on Precision Medicine, University of California, San Francisco, United States. Electronic address:
The 340B Drug Pricing Program incentivizes healthcare providers to increase medication use. It does this by allowing certain safety-net hospitals and clinics to purchase outpatient drugs at considerable discounts from manufacturers but be reimbursed at full price by payers. Yet, previous literature has left largely unstudied how the 340B program influences physician prescribing behavior.
View Article and Find Full Text PDFMinnesota Law Brings Transparency to the 340B Drug Pricing Program.
JAMA Health Forum
February 2025
Health Economics Program, Minnesota Department of Health, St Paul.
Outpatient chemotherapy drug costs and expensive chemotherapy drug use in 340B and Non-340B hospitals: an observational study.
BMC Health Serv Res
January 2025
Center for Health Policy & Health Services Research, Henry Ford Health, 1 Ford Place, Suite 5E, Detroit, MI, 48202, USA.
Background: The 340B Drug Pricing Program has been controversial since its inception in 1992, a major criticism being that 340B hospitals use more outpatient drugs, and more expensive drugs, because of financial incentives to "make money" through the program. The goal of this study was to determine whether characteristics of patients treated at 340B hospitals, and affiliation of hospitals with NCI-designated cancer centers, would explain higher Part B drug costs and use of more expensive chemotherapy drugs.
Methods: This is an observational study using data from SEER-Medicare and 340B entity database.
Determinants of HIV pre-exposure prophylaxis (PrEP) use among men who have sex with men (MSM) living in rural areas of the United States: A scoping review framed by the PrEP care continuum.
J Rural Health
January 2025
Department of Psychiatry and Behavioral Medicine, Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Background: HIV pre-exposure prophylaxis (PrEP) is a highly effective intervention to prevent HIV transmission among men who have sex with men (MSM). Despite its effectiveness, PrEP uptake and adherence among MSM in the United States remain suboptimal, particularly in rural areas.
Objective: The present study presents a scoping review of the self-reported barriers and facilitators of PrEP use among MSM living in rural areas of the United States.
The 340B Drug Pricing Program and Management of Advanced Prostate Cancer.
Cancer Med
January 2025
Department of Urology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Introduction: Oral targeted therapies are a standard of care for men with advanced prostate cancer. However, these therapies are expensive, which may be a barrier to some, particularly the most economically disadvantaged. Through investment in programs to assist this population, savings generated from the 340B program have the potential to mitigate barriers to initiating treatment with targeted therapies in these men.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!